Cover Image

A phase II study for metabolic in vivo response monitoring with sequential 18FDG-PET-CT during treatment with the EGFR-monoclonal-antibody cetuximab in metastatic colorectal cancer: the Heidelberg REMOTUX trial

The epidermal growth factor receptor monoclonal antibody cetuximab has proven activity in metastatic colorectal cancer. To date, the mechanisms of action are not completely understood. Especially the impact on tumor glucose metabolism, or tumor vascularization remains largely unclear. The understand...

Full description

Saved in:
Bibliographic Details
Main Authors: Berger, Anne Katrin (Author) , Abel, Ulrich (Author) , Kloor, Matthias (Author) , Ose, Jennifer (Author) , Weber, Tim (Author) , Stange, Annika (Author) , Haag, Georg Martin (Author) , Haberkorn, Uwe (Author) , Jäger, Dirk (Author)
Format: Article (Journal)
Language:English
Published: 22 March 2012
In: BMC cancer
Year: 2012, Volume: 12, Pages: 1-6
ISSN:1471-2407
DOI:10.1186/1471-2407-12-108
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.1186/1471-2407-12-108
Verlag, kostenfrei, Volltext: http://dx.doi.org/10.1186/1471-2407-12-108
Get full text
Author Notes:Anne Katrin Berger, Carl von Gall, Ulrich Abel, Stefan Delorme, Matthias Kloor, Jennifer Ose, Tim Frederik Weber, Annika Stange, Georg Martin Haag, Uwe Haberkorn, Florian Lordick and Dirk Jäger
Description
Summary:The epidermal growth factor receptor monoclonal antibody cetuximab has proven activity in metastatic colorectal cancer. To date, the mechanisms of action are not completely understood. Especially the impact on tumor glucose metabolism, or tumor vascularization remains largely unclear. The understanding of mechanisms such as early changes in tumor metabolism is of clinical importance since there may be a substantial influence on choice and sequence of drug combinations. Early signals of response to cetuximab may prove useful to identify patients having a relevant clinical treatment benefit. The objective of this trial is to evaluate the predictive relevance of the relative change in 18 F-Fluorodeoxyglucose tumor uptake for early clinical response during short-term single agent treatment with cetuximab. Early clinical response will be routinely measured according to the response evaluation criteria in solid tumors. Accompanying research includes cytokine immune monitoring and analysis of tumor proteins and tumor genes.
Item Description:Gesehen am 29.10.2024
Im Titel ist "18" hochgestellt
Physical Description:Online Resource
ISSN:1471-2407
DOI:10.1186/1471-2407-12-108

Similar Items